Septerna's Q4 Revenue Soars on $195M Novo Nordisk Payment; Net Loss Narrows
SEPN has more than doubled off its 52-week low of $4.66 on elevated volume (1.8× avg).
Summary
Septerna reported strong Q4 financial results, with revenue reaching $24.12 million, significantly surpassing analyst expectations of $17.33 million. The company also successfully narrowed its net loss to $10.7 million from $20.7 million in the prior year. A key driver for the revenue increase was a material $195 million upfront payment received from Novo Nordisk as part of a collaboration. This positive financial update, which includes a projected cash runway into 2029, follows recent news of positive Phase 1 clinical trial data for its lead candidate, SEP-631, supporting its advancement to Phase 2b trials. The substantial revenue beat and the significant collaboration payment are highly positive for the company's valuation and future development prospects. Traders will be watching for further updates on the SEP-631 clinical trials and the ongoing collaboration with Novo Nordisk.
At the time of this announcement, SEPN was trading at $29.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $4.66 to $32.63. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.